tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Optimistic Buy Recommendation for DBV Technologies Driven by Viaskin Peanut’s Strong Clinical Results and Market Potential
PremiumRatingsOptimistic Buy Recommendation for DBV Technologies Driven by Viaskin Peanut’s Strong Clinical Results and Market Potential
6d ago
DBV Technologies price target raised to $51 from $35 at Guggenheim
Premium
The Fly
DBV Technologies price target raised to $51 from $35 at Guggenheim
6d ago
DBV Technologies price target raised to $45 from $21 at Citizens
Premium
The Fly
DBV Technologies price target raised to $45 from $21 at Citizens
6d ago
DBV Technologies reports VITESSE trial meets primary endpoint
PremiumThe FlyDBV Technologies reports VITESSE trial meets primary endpoint
7d ago
DBV Technologies trading halted, news pending
Premium
The Fly
DBV Technologies trading halted, news pending
7d ago
DBV Technologies initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
DBV Technologies initiated with an Overweight at Cantor Fitzgerald
8d ago
Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments
PremiumRatingsOptimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments
1M ago
DBV Technologies announces last patient visit completed in VITESSE trial
Premium
The Fly
DBV Technologies announces last patient visit completed in VITESSE trial
1M ago
DBV Technologies appoints Kevin Trapp as chief commercial officer
Premium
The Fly
DBV Technologies appoints Kevin Trapp as chief commercial officer
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100